Our co-hosts welcome Dr. Scott Delacroix and Dr. Himanshu Nagar to discuss bladder cancer, bladder preservation, and the newly activated NRG-GU015 (ARCHER) clinical trial. In this episode, the experts explore who may benefit from bladder-sparing chemoradiation, dispel common misconceptions about organ preservation, and explain how GU015 is evaluating a shorter, adaptive radiation treatment approach that could make curative therapy more accessible for patients with muscle-invasive bladder cancer. They also discuss the importance of multidisciplinary care, patient-centered decision-making, and how innovations in radiation therapy and systemic treatments are shaping the future of bladder cancer care. Whether you're a clinician, researcher, or simply interested in advances in oncology, this episode offers valuable insights into a trial designed to improve both outcomes and quality of life for patients.

For Glioblastoma Awareness Day we discuss the NRG-CC017 study of TMPRT + Temozolomide for glioblastoma with PI, Dr. Huang. We also discuss the challenges faced by larger institutions with Dr. Abraham.

This special Uterine Cancer Month episode includes three different perspectives in Uterine Cancer research. First we interview uterine and ovarian cancer survivor, NRG PAC Member, and Uterine Corpus Subcommittee Patient Advocate, Anna Wilson. Second we look at the recently activated NRG-GY035 clinical study with PI Dr. Amanda Fader. Lastly we discuss uterine cancer research within NRG with Gynecologic Cancer Committee Chair, Dr. Carol Aghajanian.

In this episode, we discuss the results of the combined analysis of the prostate cancer studies RTOG 9202, 9413, 9902, and 0521 as well as learn more about translational science at NRG.

Our Podcast Co-Hosts interview NRG-GY018 study PI, Dr. Ramez Eskander on the reported mature results of the study in advanced or recurrent endometrial cancer at ASCO 2026.

The NRG Oncology Podcast discusses the American Society for Radiation Oncology’s (ASTRO) vision and goals, collaborations with cooperative groups such as NRG Oncology, and overcoming obstacles in radiation oncologywith ASTRO’s CEO, Dr. Vivek Kavadi. This is a special episode for ASTRO's 2026 Advocacy Day.

Our co-hosts interview Dr. Amanda Nickles Fader on the recently present results of NRG-GY019.

Our co-hosts discuss the NRG-BR009 'OFSET' study for premenopausal ER-positive/HER2-negative breast cancer patients that have a high risk of cancer returning with study team members Dr. Shannon Puhalla and Dr. Sandra Swain. Also on this episode, we interview Dr. Haane Massarotti on her own experience facing breast cancer as a young adult.

American Medical Association President, Dr. Bobby Mukkamala, discusses how his personal experiences in his cancer journey impact his outlook and goals in his AMA Presidency & Dr. James Yu discusses his experiences using patient-reported outcomes from clinical research to help guide health policy.

Our co-hosts interview NRG-HN009 PI Dr. Paul Harari on the recently reported initial results of NRG-HN009 at the 2026 Multidisciplary Head and Neck Cancer Symposium. Additionally, this episode discusses NRG-HN010 for HER2-expressing salivary gland cancer with Study PI, Dr. Alan Ho.